Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Humanization of the murine anti-human CD3 monoclonal antibody OKT3.

Adair JR, Athwal DS, Bodmer MW, Bright SM, Collins AM, Pulito VL, Rao PE, Reedman R, Rothermel AL, Xu D, et al.

Hum Antibodies Hybridomas. 1994;5(1-2):41-7.

PMID:
7858182
2.

Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.

Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA.

J Immunol. 1992 May 1;148(9):2756-63.

PMID:
1533410
3.

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.

Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C, Vasquez M, Tso JY.

Transplantation. 1999 Aug 27;68(4):563-71.

PMID:
10480417
4.

Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.

Cole MS, Anasetti C, Tso JY.

J Immunol. 1997 Oct 1;159(7):3613-21.

PMID:
9317161
5.

In vitro characterization of five humanized OKT3 effector function variant antibodies.

Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.

Cell Immunol. 2000 Feb 25;200(1):16-26.

PMID:
10716879
6.

Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody.

Arakawa F, Kuroki M, Kuwahara M, Senba T, Ozaki H, Matsuoka Y, Misumi Y, Kanda H, Watanabe T.

J Biochem. 1996 Sep;120(3):657-62.

7.

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.

Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA.

J Immunol. 1992 Jun 1;148(11):3461-8.

PMID:
1534096
8.

Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.

Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.

J Immunol Methods. 2004 Feb 1;285(1):111-27.

PMID:
14871540
9.
10.
11.

Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.

Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.

Int J Cancer Suppl. 1992;7:45-50.

PMID:
1428403
12.

Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.

Silva HM, Vieira PM, Costa PL, Pimentel BM, Moro AM, Kalil J, Maranhão AQ, Coelho V, Brigido MM.

Immunol Lett. 2009 Aug 15;125(2):129-36. doi: 10.1016/j.imlet.2009.06.009. Epub 2009 Jun 30.

PMID:
19573559
13.

Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.

Choi I, De Ines C, Kürschner T, Cochlovius B, Sörensen V, Olafsen T, Sandlie I, Little M.

Eur J Immunol. 2001 Jan;31(1):94-106.

14.

A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.

Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.

Transplantation. 1994 Jun 15;57(11):1537-43.

PMID:
8009586
15.

Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model.

Choi I, Schmitt WE, Bähre A, Little M, Cochlovius B.

Immunol Lett. 2002 Feb 1;80(2):125-8.

PMID:
11750044
16.

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.

Hsu DH, Shi JD, Homola M, Rowell TJ, Moran J, Levitt D, Druilhet B, Chinn J, Bullock C, Klingbeil C.

Transplantation. 1999 Aug 27;68(4):545-54.

PMID:
10480415
17.

Humanization of murine monoclonal antibodies through variable domain resurfacing.

Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blättler WA, Rees AR, Guild BC.

Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):969-73.

18.

A humanized antibody that binds to the interleukin 2 receptor.

Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA.

Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029-33.

19.

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.

J Immunol. 2002 Sep 15;169(6):3076-84.

20.

Inhibition of T cell activation with a humanized anti-beta 1 integrin chain mAb.

Poul MA, Ticchioni M, Bernard A, Lefranc MP.

Mol Immunol. 1995 Feb;32(2):101-16.

PMID:
7532786

Supplemental Content

Support Center